Drug-drug interaction: Zastaprazan + Atorvastatin

The entry 'Drug-drug interaction: Zastaprazan + Atorvastatin' refers to a clinical pharmacological interaction between two distinct drugs rather than a single biological target molecule. Zastaprazan is a potassium-competitive acid blocker (P-CAB) that targets the gastric H+/K+-ATPase to treat gastroesophageal reflux disease (Source: PubMed, PMID: 36103145). Atorvastatin is an HMG-CoA reductase inhibitor used to manage dyslipidemia and prevent cardiovascular events (Source: StatPearls, NBK430779). Clinical studies have investigated the pharmacokinetic interaction between these agents because both are substrates for the cytochrome P450 3A4 (CYP3A4) enzyme system (Source: ClinicalTrials.gov, NCT05143125). Co-administration may lead to changes in the systemic exposure of Atorvastatin, which requires monitoring for safety concerns like myopathy. Consequently, this entry is classified as a drug-drug interaction profile rather than a therapeutic target.

Other names

Zastaprazan-Atorvastatin interactionJP-1366 and Atorvastatin interactionPharmacokinetic interaction of Zastaprazan and Atorvastatin

Pharmacokinetic interaction involving potential competition for the cytochrome P450 3A4 (CYP3A4) metabolic pathway and transporter-mediated clearance.